Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabilone SCHEMBL17223864 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29475614 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL11268571 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL2762240 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL563809 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL13759779 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615666 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29448222 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL15520922 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615083 | 0.99 | CNR2 (0.98) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11866 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734961-A1 | NEW METHOD OF PRODUCING AN AQUEOUS MESOPARTICLE COMPOSITION COMPRISING A LIPOPHILIC COMPOUND | BIOGNTX R&D B.V. (NL) | 2026-05-06 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097051-A1 | CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| EP-4712952-A1 | SOLID CANNABINOID COMPOSITION FOR PARENTERAL USE | Bender Analytical Holding B.V. (NL) | 2026-03-25 | — | — | EP | claimed |
| EP-4706636-A2 | A METHOD FOR CRYSTALLIZATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Nanoform Finland Oyj (FI) | 2026-03-11 | — | — | EP | claimed |
| EP-4695192-A2 | ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF | University of Connecticut (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-12514844-B1 | Cannabinoid compositions and dosage forms | Lock Box LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-4171315-A | Preparation of cis-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1979-10-16 | — | — | US | claimed |
| US-4088777-A | Hexahydro-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs | ELI LILLY AND COMPANY (US) | 1978-05-09 | — | — | US | claimed |
| US-4087545-A | Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-4087546-A | Hexahydro-dibenzo[b,d]pyran-9-ones as antiasthmatic drugs | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-4075230-A | Preparation of optically active trans-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | claimed |
| US-4064009-A | FERMENTATION WITH BACILLUS CEREUS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | claimed |
| US-4054582-A | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | claimed |
| US-3987188-A | Hexahydro-dibenzo[b,d]pyran-9-ones as sedative drugs | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | claimed |
| US-3953603-A | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | claimed |
| US-3944673-A | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs | ELI LILLY AND COMPANY (US) | 1976-03-16 | — | — | US | claimed |